RxDoctor Payments DataLook up a doctor →

Karen Steffey

Adult Health · Lyndhurst, OHNPI 1225129695

Payments from drug & device makers

$144,622in general payments, 2019–2025

Across 977 payments — averaging $148.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$95K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biohaven Pharmaceutical Holding Company Ltd.$12K
  • Amgen$10K
  • Pfizer$5K
  • Impel Pharmaceuticals LLC$4K
  • plus $7K from 14 others

What the payments were for

  • Speaking & faculty fees$126,19687%
  • Travel & lodging$4,1173%
  • Food & beverage$14,26810%
  • Education$410%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,622 in reported general payments places this provider in the 95th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$143,087
Medicare patients
78
Services billed
18,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm123$106,566
Nurtec OdtRimegepant Sulfate77$99,999
UbrelvyUbrogepant60$78,741
Aimovig AutoinjectorErenumab-Aooe52$52,452
QuliptaAtogepant38$43,373
Trokendi XrTopiramate18$37,826
Ajovy AutoinjectorFremanezumab-Vfrm32$30,123
BotoxOnabotulinumtoxina17$22,311
Sumatriptan Succinate159$17,139
Frovatriptan Succinate27$10,815
Diclofenac Potassium22$6,785
Zolmitriptan52$6,528
Naratriptan Hcl102$3,462
Eletriptan HbrEletriptan Hydrobromide31$3,225
Ondansetron Hcl31$2,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$94,859$144,425115 claims
PfizerNurtec Odt$4,662$99,99977 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$625$37,82618 claims
Upsher-smith Laboratories LLCTopiramate$237$64693 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,184 adult health providers in Ohio.

Other adult health in Lyndhurst

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →